Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
122 Results for "
RIPK1
" in MedChemExpress (MCE) Product Catalog:
Products (122)
122 Results for "RIPK1" in MCE Product Catalog:
Cat. No.: HY-178762S
CAS No.: 3103886-96-7
Cat. No.: HY-178163
Research Areas:
Zharp1-163 is a dual inhibitor of ferroptosis and necroptosis. Zharp1-163 effectively blocks ferroptosis by reducing reactive oxygen species (ROS) levels and inhibits necroptosis by potently and selectively targeting RIPK1 kinase activity (KD = 240 nM; IC50 = 406.1 nM). Zharp1-163 inhibits the cellular activation of RIPK1, RIPK3 and MLKL in response to necroptotic stimulation. Zharp1-163 markedly attenuates TNF-α (HY-P1875)-induced systemic inflammatory syndrome, including the prevention of TNF-α-induced mortality and hypothermia in mice. Zharp1-163 significantly alleviates acute kidney injury associated with both necroptosis and ferroptosis in models induced by Cisplatin (HY-17394) and ischemia-reperfusion. Zharp1-163 can be used for the study of diseases associated with cell death pathways, such as kidney disease [1].
Cat. No.: HY-189353
Research Areas:
RIPK1 ligand-Linker Conjugate-2 is a conjugate of a RIPK1 ligand and a linker, in which the RIPK1 ligand is RIPK1-IN-37 (HY-179235) and the linker is Boc-2,6-Diazaspiro[3.3]heptane-Py-Ph-acid (HY-189354). RIPK1 ligand-Linker Conjugate-2 can be used to synthesize RIPK1 PROTAC degraders, such as LD5095 (HY-189352) [1].
Cat. No.: HY-120600
CAS No.: 1346526-26-8
Target:
Research Areas:
Sibiriline is a specific competitive inhibitor of RIPK1 that targets the RIPK1 ATP-binding site and locks it in an inactive conformation. Sibiriline inhibits TNF-induced RIPK1-dependent necroptosis and RIPK1-dependent apoptosis, but does not protect cells from caspase-dependent apoptosis. Sibiriline protects mice from concanavalin A-induced hepatitis and has the potential to inhibit immune-dependent hepatitis. [1].
Cat. No.: HY-146757
CAS No.: 1574547-67-3
Target:
Research Areas:
RIPK1-IN-13 (Compound 8) is a potent inhibitor of RIPK1 with an IC50 value of 1139 nM. RIPK1-IN-13 blocks the activation of the necroptosis pathway via the inhibition of RIPK1. RIPK1-IN-13 has the potential for the research of inflammation diseases [1].
Cat. No.: HY-156367
CAS No.: 2561431-77-2
Target:
Research Areas:
RIPK1-IN-16 is an orally active and potent inhibitor of RIPK1. RIPK1-IN-16 inhibits excessive inflammation by blocking RIPK1-mediated necroptosis in vivo. RIPK1-IN-16 protects mouse from TNF-induced systemic inflammatory response syndrome and sepsis [1].
Cat. No.: HY-170232
Target:
Research Areas:
RIPK1-IN-29 (Compound 22) is a RIPK1 inhibitor, with an IC50 of 6.9 nM. RIPK1-IN-29 exerts anti-necroptotic (Apoptosis) activity by inhibiting RIPK1. In a TNF-α-induced in vivo inflammation model, at a dose of 10 mg/kg, RIPK1-IN-29 can protect mice from hypothermia and death. RIPK1-IN-29 can be applied to the research field of inflammatory diseases [1].
Cat. No.: HY-174820
Target:
Research Areas:
AZ'320 is an ATP-competitive necroptosis (EC50 of 4.9 μM) inhibitor and a RIPK1 (pKD of 5.45) inhibitor. AZ'320 inhibits necroptosis by inhibiting RIPK1 phosphorylation. AZ’320 prevents mortality of the mice and rescues temperature and body weight in SIRS mice models. AZ'320 can be used for researches of cancer and inflammation [1].
Cat. No.: HY-160216
CAS No.: 2682889-01-4
Target:
Research Areas:
RIPK1-IN-18 (compound i) is a potent inhibitor of RIPK1. RIPK1-IN-18 can be used in autoimmune diseases research [1].
Cat. No.: HY-175373
Target:
Research Areas:
Bispiperidin-piperazin-acetate is a PROTAC linker that can be used in the synthesis of PROTACs, such as PROTAC RIPK1 Degrader-1 (HY-175370) [1].
Cat. No.: HY-143480
CAS No.: 2755704-34-6
Target:
Research Areas:
RIPK1-IN-15 (Compound 2.5) is a potent inhibitor of RIPK1. RIPK1-IN-15 has the potential for the research neurodegenerative, autoimmune, and inflammatory diseases [1].
Cat. No.: HY-144277
CAS No.: 2173556-92-6
Target:
Research Areas:
Cat. No.: HY-157751
CAS No.: 3016304-64-3
Target:
Research Areas:
RIPK1-IN-21 (Compound I-5) is an inhibitor of RIPK1 with an EC50 value of 14.8 nM. RIPK1-IN-21 can be used in the research of neurodegenerative, autoimmune, and inflammatory diseases [1].
Cat. No.: HY-162880
CAS No.: 1358585-26-8
Target:
Research Areas:
RIPK1-IN-24 is a receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC50 value of 1.3 μM. RIPK1-IN-24 can be used for research on inflammatory diseases [1].
Cat. No.: HY-169107
Target:
Research Areas:
RIPK1-IN-25 (WL8) is a blood-brain permeable RIPK1 inhibitor with EC50 and Kd values are 19.9 and 25 nM, respectively. RIPK1-IN-25 can be used in the study of neurometabolic diseases [1].
Cat. No.: HY-157963
CAS No.: 3031534-16-1
Target:
Research Areas:
RIPK1-IN-23 (compound 19) is a RIPK1 inhibitor with potent anti-necroptotic effects in HT-29 cells (EC50 of 1.7 nM). RIPK1-IN-23 shows anti-inflammatory activities [1].
Cat. No.: HY-162928
CAS No.: 2252271-96-6
Target:
Research Areas:
RIPK1-IN-26 (Compound 8a) is a potent receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with cell anti-necroptosis potency. RIPK1-IN-26 demonstrats good metabolic stability and good binding specificity in mice. RIPK1-IN-26 is promising for research of PET imaging probe development and neurodegenerative disorders [1].
Cat. No.: HY-173574
CAS No.: 2857845-45-3
Target:
Research Areas:
RIPK1-IN-31 (Compound 36) is a selective allosteric modulator of RIPK1 (receptor-interacting protein kinase 1) with an IC50 value of 16 nM. RIPK1-IN-31 is promising for research of infectious, autoimmune, and neurodegenerative diseases [1].
Cat. No.: HY-175007
Research Areas:
RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC50 of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
